Satellos Bioscience Inc.
Satellos Bioscience develops therapeutic drugs for people with severe muscle conditions. Its lead candidate, SAT-3247, is a small molecule drug being developed for Duchenne muscular dystrophy. It is designed to inhibit the protein AAK1 and support muscle regeneration. Satellos is conducting clinical trials of SAT-3247 in adults and children with Duchenne. Satellos uses its MyoReGenX discovery platform to identify and assess potential treatments by recreating the muscle stem cell environment outside the body. The company oversees drug development through an in-house team and a network of contract research organizations, and outsources research discovery work under an agreement with OHRI. Satellos is based in Markham.
No enriched coverage for $MSLE in the last 7 days.
No SEC Form 4 filings for $MSLE in the last 30 days.
See all $MSLE insider activity →Satellos Bioscience Inc. reported a GAAP EPS of -$0.53 for Q3. The company had $53.0 million in cash and short-term investments as of Sept. 30, 2026, up from $27.7 million on Dec. 31, 2025, according to a press release.
Satellos Bioscience (NASDAQ:MSLE, TSX:MSCL) revised its BASECAMP Phase 2 trial's primary endpoint to MRI-measured fat fraction, replacing dynamometry, after FDA feedback. The study tests forazapadin in boys with Duchenne muscular dystrophy. The company expects 12-week data in Q1 2027 and believes the new measure could support accelerated approval. Forazapadin targets AAK1, aiming to treat the disease regardless of mutation status.
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) formed a Scientific Advisory Board with experts in stem cell biology and related fields. The board will advise on discoveries in stem cell biology and disease pathology. The company is developing forazapadin, an orally administered small molecule AAK1 inhibitor, for muscle repair and regeneration, currently in Phase 2 trials for Duchenne muscular dystrophy.
Recent MSLE coverage spans financial news, technology and earnings.
Satellos Bioscience Inc. reported a GAAP EPS of -$0.53 for Q3. The company had $53.0 million in cash and short-term investments as of Sept. 30, 2026, up from $27.7 million on Dec. 31, 2025, according to a press release.
The endpoint change introduces uncertainty about the trial’s path to approval and may weigh on the stock.
The advisory board announcement is unlikely to move the stock significantly.
The patent grant adds a layer of protection for the company's flagship asset, likely supporting the stock price.
Enrollment completion removes a major execution risk and sets the path toward topline data in Q1 2027, likely supporting upside.
AlphAI scores every news story that mentions MSLE with an AI model for sentiment and relevance, and aggregates insider trades from Satellos Bioscience Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Satellos Bioscience Inc. reported a GAAP EPS of -$0.53 for Q3. The company had $53.0 million in cash and short-term investments as of Sept. 30, 2026, up from $27.7 million on Dec. 31, 2025, according to a press release.
Satellos Bioscience (NASDAQ:MSLE, TSX:MSCL) revised its BASECAMP Phase 2 trial's primary endpoint to MRI-measured fat fraction, replacing dynamometry, after FDA feedback. The study tests forazapadin in boys with Duchenne muscular dystrophy. The company expects 12-week data in Q1 2027 and believes the new measure could support accelerated approval. Forazapadin targets AAK1, aiming to treat the disease regardless of mutation status.
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) formed a Scientific Advisory Board with experts in stem cell biology and related fields. The board will advise on discoveries in stem cell biology and disease pathology. The company is developing forazapadin, an orally administered small molecule AAK1 inhibitor, for muscle repair and regeneration, currently in Phase 2 trials for Duchenne muscular dystrophy.
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) received a U.S. patent for forazapadin, its lead drug candidate for treating degenerative muscle diseases. The patent, valid until 2044, covers forazapadin and related compounds, strengthening the company's IP portfolio. Satellos plans to pursue FDA approval and list the patent in the Orange Book.
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) completed enrollment for its Phase 2 BASECAMP trial of forazapadin for Duchenne muscular dystrophy. The trial, involving 18 sites globally, aims to assess safety, tolerability, and muscle force improvement. Satellos plans to share topline data in Q1 2027, adjusting from earlier plans to compile a comprehensive dataset.
Satellos Bioscience (MSLE) received FDA clearance for forazapadin to treat facioscapulohumeral muscular dystrophy (FSHD). The company plans a Phase 2 study in Q4 2026, with FSHD Canada Foundation providing up to $5M in funding. Forazapadin is also in Phase 2 trials for Duchenne muscular dystrophy (DMD).
Satellos Bioscience (MSLE) announced the WHO assigned the INN forazapadin to its lead drug candidate, SAT-3247, for treating DMD and other muscle diseases. The company expects to complete enrollment in the BASECAMP Phase 2 study by Q3 2026 and release data in Q4. It also plans to start a Phase 2 trial for FSHD by year-end. The stock closed at $9.18, up 2.00%.
A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.
Satellos Bioscience (NASDAQ:MSLE) reported early results for SAT-3247 in its TRAILHEAD adult DMD study. In four participants, biceps brachii muscle fat fraction improved 3.7 points (49.7% to 46.0%) by day 140, with TE99c rising about 34% and creatine kinase down 38%. BASECAMP readout is expected in Q4.
Satellos Bioscience (NASDAQ: MSLE, TSX: MSCL) reported six-month interim TRAILHEAD data for SAT-3247 in four adults with Duchenne muscular dystrophy. Mean muscle fat fraction fell 3.7% (49.7% to 46.0%), TE99C effort rose about 34% (16.1 to 21.6 J/kg), CK fell 38% (2130 to 1315 u/l), and safety was favorable. A call is scheduled July 8.
